2013
Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System
Schuijt TJ, Bakhtiari K, Daffre S, DePonte K, Wielders SJ, Marquart JA, Hovius JW, van der Poll T, Fikrig E, Bunce MW, Camire RM, Nicolaes GA, Meijers JC, van ‘t Veer C. Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System. Circulation 2013, 128: 254-266. PMID: 23817575, PMCID: PMC3826089, DOI: 10.1161/circulationaha.113.003191.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnticoagulantsArthropod ProteinsBlood CoagulationBlood Coagulation TestsDose-Response Relationship, DrugFactor VFactor XaFactor Xa InhibitorsFeeding BehaviorFibrinogenHumansIxodesMutagenesisProtein Structure, TertiaryRabbitsRecombinant ProteinsSalivary Proteins and PeptidesSurface Plasmon ResonanceThrombin
2008
Salp15 Binding to DC-SIGN Inhibits Cytokine Expression by Impairing both Nucleosome Remodeling and mRNA Stabilization
Hovius JW, de Jong MA, Dunnen J, Litjens M, Fikrig E, van der Poll T, Gringhuis SI, Geijtenbeek TB. Salp15 Binding to DC-SIGN Inhibits Cytokine Expression by Impairing both Nucleosome Remodeling and mRNA Stabilization. PLOS Pathogens 2008, 4: e31. PMID: 18282094, PMCID: PMC2242833, DOI: 10.1371/journal.ppat.0040031.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBorrelia burgdorferiCell Adhesion MoleculesCells, CulturedCytokinesDendritic CellsDose-Response Relationship, DrugHumansIxodesLectins, C-TypeNucleosomesProtein BindingProto-Oncogene Proteins c-rafReceptors, Cell SurfaceRecombinant ProteinsRNA, MessengerSalivary Proteins and PeptidesToll-Like ReceptorsConceptsRaf-1B. burgdorferi infectionSerine/threonine kinase Raf-1Mitogen-activated protein kinase kinaseKinase Raf-1Post-transcriptional levelLyme diseaseProtein kinase kinaseRaf-1 activationBurgdorferi infectionDC-SIGNTNF-alpha mRNA stabilityHuman dendritic cell functionNucleosome remodelingTick salivary proteinsDendritic cell functionKinase kinasePro-inflammatory cytokinesAdaptive immune responsesToll-like receptorsMRNA stabilityMRNA stabilizationT cell activationMolecular mechanismsMajor vector
2000
Gamma Interferon Dominates the Murine Cytokine Response to the Agent of Human Granulocytic Ehrlichiosis and Helps To Control the Degree of Early Rickettsemia
Akkoyunlu M, Fikrig E. Gamma Interferon Dominates the Murine Cytokine Response to the Agent of Human Granulocytic Ehrlichiosis and Helps To Control the Degree of Early Rickettsemia. Infection And Immunity 2000, 68: 1827-1833. PMID: 10722570, PMCID: PMC97354, DOI: 10.1128/iai.68.4.1827-1833.2000.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBacteremiaConcanavalin ACytokinesDisease ProgressionDose-Response Relationship, DrugEhrlichiosisEnzyme-Linked Immunosorbent AssayFemaleHL-60 CellsHumansImmunoglobulin GInterferon-gammaMiceMice, Inbred C3HNeutrophilsReverse Transcriptase Polymerase Chain ReactionRickettsiaSpleenTime FactorsT-LymphocytesConceptsIFN-gamma-deficient miceHuman granulocytic ehrlichiosisIFN-gamma levelsDay 8Cytokine responsesIFN-gammaGamma interferonCells/HGE bacteriaGranulocytic ehrlichiosisIFN-gamma-independent mechanismMurine cytokine responsesTime pointsAgent of HGEMore IFN-gammaC3H/HeNLess interleukin-4IFN-gamma responsesMurine infection modelLater time pointsObligate intracellular bacteriumTh1 phenotypeC57BL/6 miceDNA burdenImmunocompetent mice
1995
Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease
Schoen R, Meurice F, Brunet C, Cretella S, Krause D, Craft J, Fikrig E. Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease. The Journal Of Infectious Diseases 1995, 172: 1324-1329. PMID: 7594671, DOI: 10.1093/infdis/172.5.1324.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, BacterialAntibody FormationAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayHumansImmunization ScheduleImmunoglobulin GLipoproteinsLyme DiseaseProspective StudiesSafetyVaccines, SyntheticConceptsSide effectsLyme diseaseOspA vaccinePrevious Lyme diseaseThree-dose scheduleLocal side effectsSystemic side effectsLyme vaccineMild arthralgiaVaccine doseThird doseProspective studyOspA antibodiesHealthy volunteersOuter surface proteinsVaccinePatientsDiseaseImmunogenicityDoseMonthsSubjectsSurface proteinsSafetyArthralgia